BIGBEAR
PHARMACEUTICAL
Cabozantinib is an oral multi-targeted tyrosine kinase inhibitor with broad-spectrum anticancer activity.
AuthenticGuaranteeFast DeliveryPrivacy December 19, 2017 — South San Francisco, CA — (Business Wire)Exelixis, Inc. (NASDAQ: EXEL) announced that the U.S. Food and Drug Administration (FDA) ···【More】
Update: 11 May,2026Source: BigbearViews: 164
March 31, 2025 (HealthDay) — According to a press release issued by the Dana-Farber Cancer Institute:The U.S. Food and Drug Administration (FDA) has a···【More】
Update: 09 May,2026Source: BigbearViews: 165
Cabozantinib is not a chemotherapy drug; rather, it is a targeted therapy medication. It works by targeting specific enzymes that are typically closel···【More】
Update: 09 May,2026Source: BigbearViews: 160
Cabozantinib cannot cure cancer. Cabozantinib is a tyrosine kinase inhibitor that is currently approved for the treatment of the following types of ca···【More】
Update: 09 May,2026Source: BigbearViews: 193
Cabozantinib is a broad-spectrum anticancer drug with multiple targets, inhibiting at least nine targets including MET, VEGFR1/2/3, ROS1, RET, AXL, NT···【More】
Update: 05 Mar,2026Source: BigbearViews: 176
Cabozantinib is a small-molecule, multi-target tyrosine kinase inhibitor developed by Exelixis in the United States. In November 2012, the FDA first a···【More】
Update: 05 Mar,2026Source: BigbearViews: 166
Cabozantinib is a broad-spectrum, multi-target anti-tumor drug developed by Exelixis Biopharmaceuticals, Inc. While most anti-tumor drugs target 1-3 t···【More】
Update: 05 Mar,2026Source: BigbearViews: 168
Cabozantinib (Cabometyx), first approved by the FDA in 2012, is a non-specific tyrosine kinase inhibitor. It exerts its anti-tumor effect by targeting···【More】
Update: 05 Mar,2026Source: BigbearViews: 164
Cabozantinib (Cabometyx), first approved by the FDA in 2012, is a non-specific tyrosine kinase inhibitor. It exerts its anti-tumor effect by targeting···【More】
Update: 03 Mar,2026Source: BigbearViews: 172
Cabozantinib is a broad-spectrum, multi-target anti-tumor drug developed by Exelixis Biopharmaceuticals, Inc. While most anti-tumor drugs target 1-3 t···【More】
Update: 28 Feb,2026Source: BigbearViews: 168
Cabozantinib is a small-molecule, multi-target tyrosine kinase inhibitor developed by Exelixis in the United States. In November 2012, the FDA first a···【More】
Update: 28 Feb,2026Source: BigbearViews: 178
Cabozantinib is a broad-spectrum anticancer drug targeting multiple targets, inhibiting at least nine targets including MET, VEGFR1/2/3, ROS1, RET, AX···【More】
Update: 28 Feb,2026Source: BigbearViews: 158
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
